144 related articles for article (PubMed ID: 19263517)
1. ErbB2 and ErbB4 Cbl binding sites can functionally replace the ErbB1 Cbl binding site.
Jansen SM; Sleumer LS; Damen E; Meijer IM; van Zoelen EJ; van Leeuwen JE
Cell Signal; 2009 May; 21(5):810-8. PubMed ID: 19263517
[TBL] [Abstract][Full Text] [Related]
2. Cbl and Itch binding sites in ERBB4 CYT-1 and CYT-2 mediate K48- and K63-polyubiquitination, respectively.
Meijer IM; van Rotterdam W; van Zoelen EJ; van Leeuwen JE
Cell Signal; 2013 Feb; 25(2):470-8. PubMed ID: 23153581
[TBL] [Abstract][Full Text] [Related]
3. Recycling of EGFR and ErbB2 is associated with impaired Hrs tyrosine phosphorylation and decreased deubiquitination by AMSH.
Meijer IM; van Rotterdam W; van Zoelen EJ; van Leeuwen JE
Cell Signal; 2012 Nov; 24(11):1981-8. PubMed ID: 22800866
[TBL] [Abstract][Full Text] [Related]
4. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers.
Muthuswamy SK; Gilman M; Brugge JS
Mol Cell Biol; 1999 Oct; 19(10):6845-57. PubMed ID: 10490623
[TBL] [Abstract][Full Text] [Related]
5. EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins.
Davies GC; Ryan PE; Rahman L; Zajac-Kaye M; Lipkowitz S
Oncogene; 2006 Oct; 25(49):6497-509. PubMed ID: 16702950
[TBL] [Abstract][Full Text] [Related]
6. ERBB2 is a target for USP8-mediated deubiquitination.
Meijer IM; van Leeuwen JE
Cell Signal; 2011 Feb; 23(2):458-67. PubMed ID: 21044682
[TBL] [Abstract][Full Text] [Related]
7. Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF receptor-mediated epithelial cell adherens junction dynamics and cell migration.
Duan L; Raja SM; Chen G; Virmani S; Williams SH; Clubb RJ; Mukhopadhyay C; Rainey MA; Ying G; Dimri M; Chen J; Reddi AL; Naramura M; Band V; Band H
J Biol Chem; 2011 Jan; 286(1):620-33. PubMed ID: 20940296
[TBL] [Abstract][Full Text] [Related]
8. Serine mutations that abrogate ligand-induced ubiquitination and internalization of the EGF receptor do not affect c-Cbl association with the receptor.
Oksvold MP; Thien CB; Widerberg J; Chantry A; Huitfeldt HS; Langdon WY
Oncogene; 2003 Nov; 22(52):8509-18. PubMed ID: 14627991
[TBL] [Abstract][Full Text] [Related]
9. Cbl controls EGFR fate by regulating early endosome fusion.
Visser Smit GD; Place TL; Cole SL; Clausen KA; Vemuganti S; Zhang G; Koland JG; Lill NL
Sci Signal; 2009 Dec; 2(102):ra86. PubMed ID: 20029031
[TBL] [Abstract][Full Text] [Related]
10. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
Feroz K; Williams E; Riese DJ
Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
[TBL] [Abstract][Full Text] [Related]
11. EGF and amphiregulin differentially regulate Cbl recruitment to endosomes and EGF receptor fate.
Stern KA; Place TL; Lill NL
Biochem J; 2008 Mar; 410(3):585-94. PubMed ID: 18045238
[TBL] [Abstract][Full Text] [Related]
12. Identification of the domain in ErbB2 that restricts ligand-induced degradation.
Shen F; Lin Q; Childress C; Yang W
Cell Signal; 2008 Apr; 20(4):779-86. PubMed ID: 18255265
[TBL] [Abstract][Full Text] [Related]
13. The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility.
Kiuchi T; Ortiz-Zapater E; Monypenny J; Matthews DR; Nguyen LK; Barbeau J; Coban O; Lawler K; Burford B; Rolfe DJ; de Rinaldis E; Dafou D; Simpson MA; Woodman N; Pinder S; Gillett CE; Devauges V; Poland SP; Fruhwirth G; Marra P; Boersma YL; Plückthun A; Gullick WJ; Yarden Y; Santis G; Winn M; Kholodenko BN; Martin-Fernandez ML; Parker P; Tutt A; Ameer-Beg SM; Ng T
Sci Signal; 2014 Aug; 7(339):ra78. PubMed ID: 25140053
[TBL] [Abstract][Full Text] [Related]
14. [Ubiquitination of EGF receptors with C-terminal domain deletion and point mutations during endocytosis].
Kondratov KA; Melikova MS; Chernorudskiĭ AL; Kornilova ES
Tsitologiia; 2009; 51(7):617-23. PubMed ID: 19764654
[TBL] [Abstract][Full Text] [Related]
15. αPIX Is a Trafficking Regulator that Balances Recycling and Degradation of the Epidermal Growth Factor Receptor.
Kortüm F; Harms FL; Hennighausen N; Rosenberger G
PLoS One; 2015; 10(7):e0132737. PubMed ID: 26177020
[TBL] [Abstract][Full Text] [Related]
16. Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.
Stoll SW; Kansra S; Peshick S; Fry DW; Leopold WR; Wiesen JF; Sibilia M; Zhang T; Werb Z; Derynck R; Wagner EF; Elder JT
Neoplasia; 2001; 3(4):339-50. PubMed ID: 11571634
[TBL] [Abstract][Full Text] [Related]
17. Erbin interacts with c-Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing c-Cbl-mediated ubiquitination and down-regulation of EGFR.
Yao S; Zheng P; Wu H; Song LM; Ying XF; Xing C; Li Y; Xiao ZQ; Zhou XN; Shen T; Chen L; Liu YH; Lai MD; Mei L; Gao TM; Li JM
J Pathol; 2015 May; 236(1):65-77. PubMed ID: 25521828
[TBL] [Abstract][Full Text] [Related]
18. Endocytosis and intracellular trafficking of ErbBs.
Sorkin A; Goh LK
Exp Cell Res; 2008 Oct; 314(17):3093-106. PubMed ID: 18793634
[TBL] [Abstract][Full Text] [Related]
19. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4.
Fitzpatrick VD; Pisacane PI; Vandlen RL; Sliwkowski MX
FEBS Lett; 1998 Jul; 431(1):102-6. PubMed ID: 9684874
[TBL] [Abstract][Full Text] [Related]
20. Intersectin 1 enhances Cbl ubiquitylation of epidermal growth factor receptor through regulation of Sprouty2-Cbl interaction.
Okur MN; Ooi J; Fong CW; Martinez N; Garcia-Dominguez C; Rojas JM; Guy G; O'Bryan JP
Mol Cell Biol; 2012 Feb; 32(4):817-25. PubMed ID: 22158968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
